1.
Secondary hyperparathyroidism: Review of the disease and its treatment
by de Francisco, Angel L.M
Clinical therapeutics, 2004, Vol.26 (12), p.1976-1993

2.
Cardiovascular Morbidity and Pure Red Cell Aplasia Associated With Epoetin Theta Therapy in Patients With Chronic Kidney Disease: A Prospective, Noninterventional, Multicenter Coho...
by Lammerich, Andreas, MD
Clinical therapeutics, 2016, Vol.38 (2), p.276-287.e4

3.
Cost-Effectiveness of Lanthanum Carbonate in the Treatment of Hyperphosphatemia in Dialysis Patients: A Canadian Payer Perspective
by Vegter, Stefan, PharmD, PhD
Clinical therapeutics, 2012, Vol.34 (7), p.1531-1543

4.
Cost-Minimization Analysis of Lanthanum Carbonate Versus Sevelamer Hydrochloride in US Patients With End-stage Renal Disease
by Keith, Michael S., PharmD, PhD
Clinical therapeutics, 2014, Vol.36 (9), p.1276-1286

5.
Economic Evaluation of Sevelamer versus Calcium-Based Binders in Treating Hyperphosphatemia among Patients with End-Stage Renal Disease in China
by Yang, Li, PhD
Clinical therapeutics, 2016, Vol.38 (11), p.2459-2467.e1

6.
Comparison of the Efficacy and Safety Profile of Morning Administration of Controlled-release Simvastatin Versus Evening Administration of Immediate-release Simvastatin in Chronic...
by Yi, Yong Jin, MD
Clinical therapeutics, 2014, Vol.36 (8), p.1182-1190

7.
Assessment of Pharmacodynamic Equivalence and Tolerability of Lanthanum Carbonate Oral Powder and Tablet Formulations: A Single-Center, Randomized, Open-Label, 2-Period Crossover S...
by Pierce, David, PhD
Clinical therapeutics, 2012, Vol.34 (6), p.1290-1300.e2

8.
Pulmonary Embolism Inpatients Treated With Rivaroxaban Had Shorter Hospital Stays and Lower Costs Compared With Warfarin
by Margolis, Jay M., PharmD
Clinical therapeutics, 2016, Vol.38 (11), p.2496-2503
